Countries with the second highest number of infections held vaccine drills to prepare for vaccination campaigns.
Coronavirus – most recent updates
View our full coverage of coronaviruses
The Covid-19 vaccine developed by AstraZeneca and Oxford University has been approved by India, paving the way for a large-scale vaccination campaign in the second most populated country in the world. Prakash Javadekar, Minister of Media and Broadcasting, said Saturday that the vaccine was given the green light on Friday. It is the first emergency Covid-19 vaccine approved in India, the country with the second-highest rate of infection after the United States. The decision came on the same day as a national vaccine distribution exercise in which health workers obtained dummy vaccines to be used throughout the country at each of the centers. Health Minister Harsh Vardhan said the exercise would help develop expertise “so that the upcoming vaccination drive can continue without any interruption.” Javadekar said at least three other vaccines are pending approval – Co Co. “One was approved yesterday for emergency use, Covishield from Serum,” he said. The Oxford/AstraZeneca vaccine is produced locally by the Serum Institute of India (SII). The dosage and other details are expected to be announced later by the Central Drugs Standard Control Organization (CDSCO) of India.
The Oxford/AstraZeneca vaccine, which was first authorized in the U.K. It is cheaper and easier to manage on Tuesday than certain competing drugs – crucial advantages in fighting a pandemic that has taken more than 1.8 million lives worldwide – but there was disagreement about the most effective dosage, with data released in November showing that a half dose followed by a full dose had a 90% success rate, while two full shots were 62% effective. An emergency application for the vaccine produced by Pfizer and German firm BioNTech, the first to be approved in the West, has also been received by India’s regulator. India has reported more than 10 million cases of covid, although the infection rate has dropped significantly since a peak in mid-September. In the first six to eight months of the year, the country hopes to vaccinate 300 million of its 1.35 billion population. SII, the largest vaccine producer in the world, has already stockpiled 50 million doses of the Oxford/AstraZeneca medicine, which will be marketed at 250 rupees (£2.50) per dose to the government and at 1,000 rupees on the private market. In the U.K. This week, Argentina approved the Oxford/AstraZeneca vaccine and on Thursday, the World Health Organization granted emergency approval to the Pfizer/BioNTech vaccine. Covishield is likely to be used more often in India since it can be processed and transported under normal conditions of refrigeration. Products from Pfizer must be held at extremely low temperatures.